Friday, 21 August 2026

Indian corporate news, decoded into deal flow

NSE LIVE
NIFTY 50 INDIA VIX
as of
MARKETS
DEAL FLOW
Rane (Madras) Q1 FY27 Earnings: Revenue… ▲ Mergers & Acquisitions Virtuoso Optoelectronics Q1 FY27 Earnings Call:… ▲ Results Max Estates Q1 FY27: Strong ₹1,100… ▲ Results Ashok Leyland Q1 FY27: Record Revenue… ▲ Results Ceigall India Secures ₹225 Crore Bulk… ▲ Order Book Glenmark Pharmaceuticals Launches Calcium Gluconate Injection… ▲ Capex & Future Plan Tata Motors Passenger Vehicles to Increase… ▲ Market News / Economy
>
Home / Order Book / Ceigall India Secures ₹225 Crore Bulk Drug Park Order in Himachal Pradesh
OB · Order Book

Ceigall India Secures ₹225 Crore Bulk Drug Park Order in Himachal Pradesh

Ceigall India Limited has strengthened its infrastructure order pipeline after receiving a Letter of Award (LOA) worth ₹225 crore, including GST, from Himachal Pradesh State Industrial Development Corporation Limited (HPSIDC) for the development of the Bulk Drug Park at Una, Himachal Pradesh. The company disclosed the award on August 21, 2026, stating that the project will further expand its geographical presence and diversify its infrastructure portfolio.

₹225 Crore Order From HPSIDC

Ceigall India received the LOA from HPSIDC through an email dated August 20, 2026. The project, titled “Development of Bulk Drug Park at Una, District Una, Himachal Pradesh – Phase I,” involves formation cutting, construction of internal roads, stormwater drains, a bridge and fencing.

The contract has been awarded as an item-rate contract, with a performance security requirement of 3% of the contract value. The total awarded cost stands at ₹225 crore, including GST.

Project to Be Completed in 18 Months

The project has an execution period of 18 months. The scope covers critical infrastructure required for the development of the Bulk Drug Park, including internal road connectivity, drainage systems, bridge construction and fencing.

The development is expected to provide essential infrastructure for an industrial ecosystem focused on the bulk drug sector and could contribute to the broader industrial development of Una and Himachal Pradesh.

Strengthening Pan-India Presence

The latest order adds to Ceigall India’s growing portfolio across different geographies and infrastructure segments. The company said the project reinforces its strategy of expanding its geographic footprint while participating in infrastructure projects aligned with India’s evolving industrial and economic requirements.

For Ceigall India, diversification beyond conventional road and highway projects into infrastructure supporting industrial development provides another avenue for expanding its addressable project opportunity.

Management Commentary

Commenting on the order, Ramneek Sehgal, Managing Director, Ceigall India Limited, said the Una Bulk Drug Park project marks another important milestone in the company’s growth journey. He highlighted the company’s expanding order portfolio across geographies and infrastructure segments and said the award reflects the confidence placed in Ceigall India’s execution capabilities.

The management also reiterated its commitment to contributing to infrastructure development supporting industrial growth, connectivity and India’s broader long-term economic development goals.

Importance of the Bulk Drug Park Project

The Bulk Drug Park project is strategically linked to the development of India’s pharmaceutical and industrial ecosystem. The infrastructure work covered under Ceigall India’s contract includes roads, drainage, bridges, and fencing, which are essential for establishing the supporting infrastructure for the industrial park.

While Ceigall India is responsible for the infrastructure works specified in the awarded contract, the broader development of the park could support industrial activity and connectivity in the region.

No Related Party Interest

According to the company’s disclosure, the order has been awarded by a domestic entity, HPSIDC. Ceigall India stated that neither its promoter/promoter group nor group companies have any interest in the entity awarding the contract. The company also confirmed that the contract does not fall under related-party transactions.

Ceigall India’s Business Profile

Ceigall India Limited is an infrastructure EPC company involved in the development of highways, expressways, bridges, flyovers, railway overbridges, tunnels and runways. The company executes projects under both EPC and Hybrid Annuity Model (HAM) formats and has a presence across multiple states in India.

The company said its growing order book and diversified project portfolio position it to participate in India’s infrastructure development across multiple segments.

Key Takeaways for Investors

  • Ceigall India received a Letter of Award from HPSIDC.
  • The order value is ₹225 crore including GST.
  • The project involves development of Bulk Drug Park at Una, Himachal Pradesh.
  • The scope includes formation cutting, internal roads, stormwater drains, bridge construction and fencing.
  • The project is scheduled for completion within 18 months.
  • The contract is an item-rate contract.
  • Performance security is 3% of the contract value.
  • The order strengthens Ceigall India’s geographical presence and infrastructure portfolio.
  • The company stated that there is no promoter or group-company interest in the awarding entity.
  • The contract is not a related-party transaction.

Stock Market Impact

The order is positive for Ceigall India from an order-book and revenue visibility perspective, as the ₹225 crore award adds to the company’s project pipeline and strengthens its presence in a new infrastructure segment linked to industrial development. The actual impact on revenue and profitability will depend on project execution, margins, working-capital requirements and the pace of billing over the 18-month execution period.

The order also highlights Ceigall India’s strategy of diversifying its infrastructure portfolio and expanding beyond individual geographic markets. Investors should track subsequent disclosures regarding order-book growth, execution progress and project margins.

Disclaimer: This article is based on information disclosed by Ceigall India Limited through its stock exchange filing and press release. The article is intended for informational and educational purposes only and should not be considered investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.